Investors & Media

Corporate Profile

We are a vertically integrated, clinical stage gene therapy company with six ongoing clinical programs and a broad pipeline of preclinical and research programs. We have core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, we have taken a portfolio approach by licensing, acquiring and developing technologies that give us depth across both product candidates and indications. Our current focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia and xerophthalmia. Though initially focusing on the eye, salivary gland and central nervous system, we intend to expand our focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

Investor Overview

Common Stock


Change (%)


Data as of: 07/16/24 3:27 am EDT.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Contact

Email Address:

Media Contact

Ben Rickles
Associate Director, Real Chemistry

(404) 502-6766